ELAVL1 and breast cancer: CRISPR/Cas9 induced KO of HuR in BC cell line MDA-MB-231 and pancreatic cancer cell line MIAPaCa2 led to significant reduction of PD-L1 protein levels in comparison with that of sgControl (Fig. 1c).